|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: PLCL1 |
Gene summary for PLCL1 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | PLCL1 | Gene ID | 5334 |
| Gene name | phospholipase C like 1 (inactive) | |
| Gene Alias | PLCE | |
| Cytomap | 2q33.1 | |
| Gene Type | protein-coding | GO ID | GO:0001659 | UniProtAcc | Q15111 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 5334 | PLCL1 | RNA-P10T2-P10T2-2 | Human | Lung | AAH | 1.65e-02 | 7.60e-01 | -0.1406 |
| 5334 | PLCL1 | RNA-P10T2-P10T2-3 | Human | Lung | AAH | 2.72e-02 | 6.42e-01 | -0.1408 |
| 5334 | PLCL1 | RNA-P10T2-P10T2-4 | Human | Lung | AAH | 1.10e-02 | 7.68e-01 | -0.138 |
| 5334 | PLCL1 | RNA-P25T1-P25T1-1 | Human | Lung | AIS | 3.18e-22 | 9.05e-01 | -0.2116 |
| 5334 | PLCL1 | RNA-P25T1-P25T1-2 | Human | Lung | AIS | 4.08e-03 | 5.66e-01 | -0.1941 |
| 5334 | PLCL1 | RNA-P25T1-P25T1-3 | Human | Lung | AIS | 1.67e-07 | 7.41e-01 | -0.2107 |
| 5334 | PLCL1 | RNA-P25T1-P25T1-4 | Human | Lung | AIS | 2.19e-08 | 5.81e-01 | -0.2119 |
| 5334 | PLCL1 | RNA-P6T1-P6T1-1 | Human | Lung | MIAC | 2.13e-04 | 9.36e-01 | -0.0238 |
| 5334 | PLCL1 | RNA-P6T1-P6T1-2 | Human | Lung | MIAC | 1.48e-05 | 1.06e+00 | -0.0186 |
| 5334 | PLCL1 | RNA-P6T1-P6T1-3 | Human | Lung | MIAC | 3.67e-02 | 7.89e-01 | -0.0296 |
| 5334 | PLCL1 | RNA-P6T1-P6T1-4 | Human | Lung | MIAC | 2.37e-08 | 1.06e+00 | -0.0263 |
| Page: 1 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Lung |  | AAH: Atypical adenomatous hyperplasia |
| AIS: Adenocarcinoma in situ | ||
| IAC: Invasive lung adenocarcinoma | ||
| MIA: Minimally invasive adenocarcinoma |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:001810512 | Lung | AIS | peptidyl-serine phosphorylation | 60/1849 | 315/18723 | 4.75e-07 | 3.64e-05 | 60 |
| GO:001820912 | Lung | AIS | peptidyl-serine modification | 61/1849 | 338/18723 | 2.49e-06 | 1.41e-04 | 61 |
| GO:005109813 | Lung | AIS | regulation of binding | 61/1849 | 363/18723 | 2.48e-05 | 8.06e-04 | 61 |
| GO:003209212 | Lung | AIS | positive regulation of protein binding | 19/1849 | 85/18723 | 5.23e-04 | 8.42e-03 | 19 |
| GO:004339313 | Lung | AIS | regulation of protein binding | 34/1849 | 196/18723 | 8.16e-04 | 1.14e-02 | 34 |
| GO:005109913 | Lung | AIS | positive regulation of binding | 30/1849 | 173/18723 | 1.61e-03 | 1.87e-02 | 30 |
| GO:003209222 | Lung | AAH | positive regulation of protein binding | 9/613 | 85/18723 | 1.83e-03 | 4.29e-02 | 9 |
| GO:001810521 | Lung | MIAC | peptidyl-serine phosphorylation | 37/967 | 315/18723 | 2.73e-06 | 3.12e-04 | 37 |
| GO:001820921 | Lung | MIAC | peptidyl-serine modification | 37/967 | 338/18723 | 1.38e-05 | 9.86e-04 | 37 |
| GO:00331351 | Lung | MIAC | regulation of peptidyl-serine phosphorylation | 16/967 | 144/18723 | 3.16e-03 | 4.23e-02 | 16 |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| PLCL1 | SNV | Missense_Mutation | c.839T>C | p.Ile280Thr | p.I280T | Q15111 | protein_coding | deleterious(0) | possibly_damaging(0.691) | TCGA-78-7154-01 | Lung | lung adenocarcinoma | Male | >=65 | III/IV | Unknown | Unknown | SD | |
| PLCL1 | SNV | Missense_Mutation | c.861N>G | p.Ile287Met | p.I287M | Q15111 | protein_coding | deleterious(0.02) | possibly_damaging(0.454) | TCGA-78-8640-01 | Lung | lung adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD | |
| PLCL1 | SNV | Missense_Mutation | c.867N>T | p.Lys289Asn | p.K289N | Q15111 | protein_coding | deleterious(0.03) | possibly_damaging(0.756) | TCGA-91-6828-01 | Lung | lung adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
| PLCL1 | SNV | Missense_Mutation | c.1168N>C | p.Asp390His | p.D390H | Q15111 | protein_coding | deleterious(0) | probably_damaging(0.976) | TCGA-21-5782-01 | Lung | lung squamous cell carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| PLCL1 | SNV | Missense_Mutation | novel | c.2506N>T | p.Met836Leu | p.M836L | Q15111 | protein_coding | tolerated(1) | benign(0) | TCGA-22-4594-01 | Lung | lung squamous cell carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
| PLCL1 | SNV | Missense_Mutation | c.1969N>A | p.Gln657Lys | p.Q657K | Q15111 | protein_coding | deleterious(0) | probably_damaging(0.996) | TCGA-22-4595-01 | Lung | lung squamous cell carcinoma | Male | <65 | III/IV | Chemotherapy | alimta | PD | |
| PLCL1 | SNV | Missense_Mutation | c.1865N>A | p.Arg622His | p.R622H | Q15111 | protein_coding | deleterious(0) | probably_damaging(0.997) | TCGA-22-A5C4-01 | Lung | lung squamous cell carcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
| PLCL1 | SNV | Missense_Mutation | c.1991N>C | p.Cys664Ser | p.C664S | Q15111 | protein_coding | deleterious(0) | probably_damaging(0.969) | TCGA-33-4532-01 | Lung | lung squamous cell carcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
| PLCL1 | SNV | Missense_Mutation | c.2432N>T | p.Gln811Leu | p.Q811L | Q15111 | protein_coding | deleterious(0.03) | possibly_damaging(0.651) | TCGA-33-4586-01 | Lung | lung squamous cell carcinoma | Male | <65 | III/IV | Unknown | Unknown | PD | |
| PLCL1 | SNV | Missense_Mutation | c.2370N>C | p.Glu790Asp | p.E790D | Q15111 | protein_coding | deleterious(0.01) | possibly_damaging(0.777) | TCGA-34-5231-01 | Lung | lung squamous cell carcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |